QQQ   356.46 (+0.51%)
AAPL   184.06 (+1.72%)
MSFT   338.14 (+0.82%)
META   274.23 (+0.59%)
GOOGL   126.76 (+1.68%)
AMZN   125.04 (+0.64%)
TSLA   217.37 (+1.59%)
NVDA   391.01 (-0.57%)
NIO   7.70 (+1.85%)
BABA   83.71 (-0.66%)
AMD   118.50 (+0.54%)
T   15.40 (+1.25%)
F   12.61 (+1.78%)
MU   68.14 (-1.49%)
CGC   0.79 (-4.69%)
GE   104.51 (-1.22%)
DIS   90.34 (-0.47%)
AMC   4.60 (+1.10%)
PFE   38.80 (+1.15%)
PYPL   64.57 (+0.95%)
NFLX   409.23 (+2.19%)
QQQ   356.46 (+0.51%)
AAPL   184.06 (+1.72%)
MSFT   338.14 (+0.82%)
META   274.23 (+0.59%)
GOOGL   126.76 (+1.68%)
AMZN   125.04 (+0.64%)
TSLA   217.37 (+1.59%)
NVDA   391.01 (-0.57%)
NIO   7.70 (+1.85%)
BABA   83.71 (-0.66%)
AMD   118.50 (+0.54%)
T   15.40 (+1.25%)
F   12.61 (+1.78%)
MU   68.14 (-1.49%)
CGC   0.79 (-4.69%)
GE   104.51 (-1.22%)
DIS   90.34 (-0.47%)
AMC   4.60 (+1.10%)
PFE   38.80 (+1.15%)
PYPL   64.57 (+0.95%)
NFLX   409.23 (+2.19%)
QQQ   356.46 (+0.51%)
AAPL   184.06 (+1.72%)
MSFT   338.14 (+0.82%)
META   274.23 (+0.59%)
GOOGL   126.76 (+1.68%)
AMZN   125.04 (+0.64%)
TSLA   217.37 (+1.59%)
NVDA   391.01 (-0.57%)
NIO   7.70 (+1.85%)
BABA   83.71 (-0.66%)
AMD   118.50 (+0.54%)
T   15.40 (+1.25%)
F   12.61 (+1.78%)
MU   68.14 (-1.49%)
CGC   0.79 (-4.69%)
GE   104.51 (-1.22%)
DIS   90.34 (-0.47%)
AMC   4.60 (+1.10%)
PFE   38.80 (+1.15%)
PYPL   64.57 (+0.95%)
NFLX   409.23 (+2.19%)
QQQ   356.46 (+0.51%)
AAPL   184.06 (+1.72%)
MSFT   338.14 (+0.82%)
META   274.23 (+0.59%)
GOOGL   126.76 (+1.68%)
AMZN   125.04 (+0.64%)
TSLA   217.37 (+1.59%)
NVDA   391.01 (-0.57%)
NIO   7.70 (+1.85%)
BABA   83.71 (-0.66%)
AMD   118.50 (+0.54%)
T   15.40 (+1.25%)
F   12.61 (+1.78%)
MU   68.14 (-1.49%)
CGC   0.79 (-4.69%)
GE   104.51 (-1.22%)
DIS   90.34 (-0.47%)
AMC   4.60 (+1.10%)
PFE   38.80 (+1.15%)
PYPL   64.57 (+0.95%)
NFLX   409.23 (+2.19%)
NASDAQ:PRCT

PROCEPT BioRobotics (PRCT) Stock Forecast, Price & News

$31.75
-0.75 (-2.31%)
(As of 12:02 PM ET)
Compare
Today's Range
$30.94
$32.28
50-Day Range
$26.64
$37.02
52-Week Range
$25.29
$52.40
Volume
117,856 shs
Average Volume
366,692 shs
Market Capitalization
$1.43 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.83

PROCEPT BioRobotics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
48.9% Upside
$46.83 Price Target
Short Interest
Healthy
5.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.69mentions of PROCEPT BioRobotics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$1.25 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.20) to ($1.73) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

290th out of 980 stocks

Surgical & Medical Instruments Industry

25th out of 97 stocks


PRCT stock logo

About PROCEPT BioRobotics (NASDAQ:PRCT) Stock

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

Receive PRCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter.

PRCT Stock News Headlines

PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Down 6.2%
AI industry Is Exploding! New Breakthrough Expected this Summer
Bill Gates says the AI Era has begun. Every tech company is looking to integrate artificial intelligence. A young company holds the secret to the next biggest AI advancement.
Procept BioRobotics: Adding For 2023 Rebound
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
PROCEPT BioRobotics (NASDAQ:PRCT) Shares Down 4.7%
KeyBanc Keeps Their Buy Rating on PROCEPT BioRobotics (PRCT)
PROCEPT BioRobotics (PRCT) Gets a Buy from B.Riley Financial
See More Headlines

PRCT Price History

PRCT Company Calendar

Last Earnings
4/27/2023
Today
6/05/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRCT
Fax
N/A
Employees
234
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.83
High Stock Price Forecast
$53.00
Low Stock Price Forecast
$43.00
Forecasted Upside/Downside
+44.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-87,150,000.00
Net Margins
-115.53%
Pretax Margin
-115.53%

Debt

Sales & Book Value

Annual Sales
$75.01 million
Book Value
$3.84 per share

Miscellaneous

Free Float
36,219,000
Market Cap
$1.46 billion
Optionable
Not Optionable
Beta
0.57

Key Executives

  • Dr. Reza Zadno Ph.D. (Age 68)
    Pres, CEO & Director
    Comp: $759.5k
  • Mr. Kevin Waters (Age 46)
    Exec. VP & CFO
    Comp: $543.38k
  • Mr. Hisham Shiblaq (Age 47)
    Exec. VP & Chief Commercial Officer
    Comp: $507.5k
  • Mr. Mohan F. Sancheti (Age 59)
    Sr. VP of Operations
  • Ms. Alaleh Nouri (Age 44)
    EVP, Chief Legal Officer & Corp. Sec.
  • Ms. Minni Vittal
    Sr. VP & Chief People Officer
  • Mr. Bijesh Chandran
    Sr. VP of Regulatory Affairs & Quality Assurance
  • Mr. Barry Templin
    Sr. VP of Clinical & Medical Affairs
  • Dr. Thomas J. Yorkey Ph.D. (Age 61)
    Sr. VP of R&D













PRCT Stock - Frequently Asked Questions

Should I buy or sell PROCEPT BioRobotics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PROCEPT BioRobotics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRCT shares.
View PRCT analyst ratings
or view top-rated stocks.

What is PROCEPT BioRobotics' stock price forecast for 2023?

7 Wall Street research analysts have issued 12 month target prices for PROCEPT BioRobotics' stock. Their PRCT share price forecasts range from $43.00 to $53.00. On average, they anticipate the company's stock price to reach $46.83 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price.
View analysts price targets for PRCT
or view top-rated stocks among Wall Street analysts.

How have PRCT shares performed in 2023?

PROCEPT BioRobotics' stock was trading at $41.54 on January 1st, 2023. Since then, PRCT stock has decreased by 21.8% and is now trading at $32.50.
View the best growth stocks for 2023 here
.

Are investors shorting PROCEPT BioRobotics?

PROCEPT BioRobotics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 2,200,000 shares, a decline of 15.1% from the April 30th total of 2,590,000 shares. Based on an average daily volume of 403,200 shares, the days-to-cover ratio is currently 5.5 days. Approximately 5.2% of the shares of the company are sold short.
View PROCEPT BioRobotics' Short Interest
.

When is PROCEPT BioRobotics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PRCT earnings forecast
.

How were PROCEPT BioRobotics' earnings last quarter?

PROCEPT BioRobotics Co. (NASDAQ:PRCT) posted its earnings results on Thursday, April, 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by $0.04. The business earned $24.40 million during the quarter, compared to analysts' expectations of $24.32 million. PROCEPT BioRobotics had a negative trailing twelve-month return on equity of 45.87% and a negative net margin of 115.53%. PROCEPT BioRobotics's quarterly revenue was up 71.8% on a year-over-year basis. During the same period last year, the company posted ($0.39) earnings per share.

What guidance has PROCEPT BioRobotics issued on next quarter's earnings?

PROCEPT BioRobotics issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $128.00 million-$128.00 million, compared to the consensus revenue estimate of $126.71 million.

When did PROCEPT BioRobotics IPO?

(PRCT) raised $126 million in an initial public offering on Wednesday, September 15th 2021. The company issued 5,500,000 shares at $22.00-$24.00 per share.

What is PROCEPT BioRobotics' stock symbol?

PROCEPT BioRobotics trades on the NASDAQ under the ticker symbol "PRCT."

Who are PROCEPT BioRobotics' major shareholders?

PROCEPT BioRobotics' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.94%), BlackRock Inc. (4.21%), Price T Rowe Associates Inc. MD (2.98%), State Street Corp (1.77%), Geode Capital Management LLC (1.32%) and Frank Rimerman Advisors LLC (1.01%). Insiders that own company stock include Alaleh Nouri, Global Investors Lp Viking, Hisham Shiblaq, Kevin Waters, Morgan Colby Wood, Reza Zadno and Thomas M Krummel.
View institutional ownership trends
.

How do I buy shares of PROCEPT BioRobotics?

Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PROCEPT BioRobotics' stock price today?

One share of PRCT stock can currently be purchased for approximately $32.50.

How much money does PROCEPT BioRobotics make?

PROCEPT BioRobotics (NASDAQ:PRCT) has a market capitalization of $1.46 billion and generates $75.01 million in revenue each year. The company earns $-87,150,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis.

How many employees does PROCEPT BioRobotics have?

The company employs 234 workers across the globe.

How can I contact PROCEPT BioRobotics?

PROCEPT BioRobotics' mailing address is 900 ISLAND DRIVE, REDWOOD CITY CA, 94065. The official website for the company is www.procept-biorobotics.com. The company can be reached via phone at 650-232-7200 or via email at ir@procept-biorobotics.com.

This page (NASDAQ:PRCT) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -